An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing

Journal of Virological Methods

Volumn 204, Issue , 2014, Pages 31-37

  Simen, Birgitte B ^a   Braverman, Michael S ^a   Abbate, Isabella ^b   Aerssens, Jeroen ^c   Bidet, Yannick ^d   Bouchez, Olivier ^e   Gabriel, Christian ^f   Izopet, Jacques ^g   Kessler, Harald H ^h   Stelzl, Evelyn ^h   Di Giallonardo, Francesca ⁱ   Schlapbach, Ralph ^j   Radonic, Aleksander ^k   Paredes, Roger ^l   Recordon Pinson, Patricia ^m   Sakwa, James ⁿ   St John, Elizabeth P ^a   Schmitz Agheguian, Gudrun G ^o   Metzner, Karin J ⁱ   Däumer, Martin P ^p   Danzer, M ^f   Hackl, C ^f   Proll J ^f   Niklas, N ^f   Bizon, B ^h   Van Eygen, V ^c   Vandenbroucke, I ^c   Van Marck, H ^c   Dubois, M ^g   Nicot, F ^g   Bouchez, O ^e   Milan, D ^e   Masquelier, B ^m   Recordon Pinson, P ^m   Fleury, H ^m   Viala, S ^d   Daumer M ^p   Marell, R ^p   Thiele, B ^p   Kuecherer, C ^k   Meixenberger, K ^k   Nitsche, A ^k   Dabrowski, P W ^k   Ihlenfeldt, H G ^o   Capobianchi, M R ^b   Bruselles, A ^b   Rozera, G ^b   Bartolini, B ^b   Sakwa, J ⁿ   Stephens, D ⁿ   Makgamathe, M ⁿ   Pillay, D ⁿ   Gordon, M ^q   Green, T ^q   Codoner F M ^l   Pou, C ^l   Gunthard H F ⁱ   Kunzli Gontarczyk M ^j   Bruggmann, R ^j   Qi, W ^j   Turenchalk, G ^a   Hanczaruk, B ^a   more..

^a A Roche Company   (United States)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d CENTRE JEAN PERRIN   (France)

^e CEMAGREF   (France)

^f Red Cross Transfusion Service of Upper Austria   (Austria)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j FUNCTIONAL GENOMICS CENTER ZURICH   (Switzerland)

^k ROBERT KOCH INSTITUTE   (Germany)

^l Irsicaixa AIDS Research Institute   (Spain)

^m UNIVERSITÉ DE BORDEAUX   (France)

ⁿ TIA National Genomics Platform   (South Africa)

^o ROCHE DIAGNOSTICS GMBH   (Germany)

^p Technische University   (Germany)

^q UNIVERSITY OF KWAZULU NATAL   (South Africa)

more..

Author keywords

454 ultra deep pyrosequencing; Drug resistance; HIV 1; Multicenter study; Next generation sequencing

Indexed keywords

COMPLEMENTARY DNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

454 ULTRA DEEP PYROSEQUENCING; ACCURACY; AMPLICON; ANTIVIRAL RESISTANCE; ARTICLE; AUTOANALYZER; CODON; CONTROLLED STUDY; DATA ANALYSIS; DATA ANALYSIS SOFTWARE; DNA SYNTHESIS; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; INSTRUMENT VALIDATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PYROSEQUENCING; REPRODUCIBILITY; RNA EXTRACTION; SEQUENCE ANALYSIS; BIOLOGY; CLINICAL TRIAL; COMPUTER PROGRAM; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTICENTER STUDY; PROCEDURES; VIROLOGY;

COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONAL COOPERATION; MICROBIAL SENSITIVITY TESTS; SOFTWARE;

EID: 84899506819     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.04.007     Document Type: Article

References (27)

1. Abbate I., Rozera G., Giombini E., D'Offizi G., Nicastri E., Narciso P., Ippolito G., Capobianchi M.R. Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: what is the clinical impact of the quasispecies distribution?. J. Infect. Dis. 2011, 204:971-973. author reply 973-974.
2. Avidor B., Girshengorn S., Matus N., Talio H., Achsanov S., Zeldis I., Fratty I.S., Katchman E., Brosh-Nissimov T., Hassin D., Alon D., Bentwich Z., Yust I., Amit S., Forer R., Vulih Shultsman I., Turner D. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J. Clin. Microbiol. 2013, 51:880-886.
3. Beerenwinkel N., Gunthard H.F., Roth V., Metzner K.J. Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data. Front. Microbiol. 2012, 3:329.
4. Codoner F.M., Pou C., Thielen A., Garcia F., Delgado R., Dalmau D., Alvarez-Tejado M., Ruiz L., Clotet B., Paredes R. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS ONE 2011, 6:e19461.
5. Däumer M., Kaiser R., Klein R., Lengauer T., Thiele B., Thielen A. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med. Inform. Decis. Mak. 2011, 11:30.
6. De Wolf H., Van Marck H., Mostmans W., Thys K., Vandenbroucke I., Van Eygen V., Pattery T., Verhasselt P., Aerssens J. HIV-1 nucleotide mixture detection in the virco((R))TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing. J. Virol. Methods 2011, 175:129-132.
7. Di Giallonardo F., Zagordi O., Duport Y., Leemann C., Joos B., Kunzli-Gontarczyk M., Bruggmann R., Beerenwinkel N., Gunthard H.F., Metzner K.J. Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination. PLoS ONE 2013, 8:e74249.
8. Garcia-Diaz A., Guerrero-Ramos A., McCormick A.L., Macartney M., Conibear T., Johnson M.A., Haque T., Webster D.P. Evaluation of the Roche prototype 454 HIV-1 ultradeep sequencing drug resistance assay in a routine diagnostic laboratory. J. Clin. Virol. 2013, 58:468-473.
9. Gianella S., Richman D.D. Minority variants of drug-resistant HIV. J. Infect. Dis. 2010, 202:657-666.
10. Halvas E.K., Aldrovandi G.M., Balfe P., Beck I.A., Boltz V.F., Coffin J.M., Frenkel L.M., Hazelwood J.D., Johnson V.A., Kearney M., Kovacs A., Kuritzkes D.R., Metzner K.J., Nissley D.V., Nowicki M., Palmer S., Ziermann R., Zhao R.Y., Jennings C.L., Bremer J., Brambilla D., Mellors J.W. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 2006, 44:2612-2614.
11. Hirsch M.S., Gunthard H.F., Schapiro J.M., Brun-Vezinet F., Clotet B., Hammer S.M., Johnson V.A., Kuritzkes D.R., Mellors J.W., Pillay D., Yeni P.G., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 2008, 47:266-285.
12. Hoffmann C., Minkah N., Leipzig J., Wang G., Arens M.Q., Tebas P., Bushman F.D. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res. 2007, 35:e91.
13. Lataillade M., Chiarella J., Yang R., Schnittman S., Wirtz V., Uy J., Seekins D., Krystal M., Mancini M., McGrath D., Simen B., Egholm M., Kozal M. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE 2010, 5:e10952.
14. Le T., Chiarella J., Simen B.B., Hanczaruk B., Egholm M., Landry M.L., Dieckhaus K., Rosen M.I., Kozal M.J. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE 2009, 4:e6079.
15. Li J.Z., Kuritzkes D.R. Clinical implications of HIV-1 minority variants. Clin. Infect. Dis. 2013, 56:1667-1674.
16. Metzner K.J., Bonhoeffer S., Fischer M., Karanicolas R., Allers K., Joos B., Weber R., Hirschel B., Kostrikis L.G., Gunthard H.F. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 2003, 188:1433-1443.
17. Metzner K.J., Rauch P., von Wyl V., Leemann C., Grube C., Kuster H., Boni J., Weber R., Gunthard H.F. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J. Infect. Dis. 2010, 201:1063-1071.
18. Nicot F., Saliou A., Raymond S., Saune K., Dubois M., Massip P., Marchou B., Delobel P., Izopet J. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J. Clin. Virol. 2012, 55:107-113.
19. Paredes R., Marconi V.C., Campbell T.B., Kuritzkes D.R. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J. Virol. Methods 2007, 146:136-146.
20. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31:298-303.
21. Schuurman R., Demeter L., Reichelderfer P., Tijnagel J., de Groot T., Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 1999, 37:2291-2296.
22. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., Huang C., Lubeski C., Turenchalk G.S., Braverman M.S., Desany B., Rothberg J.M., Egholm M., Kozal M.J. Low-abundance drug-resistant viral variants in chronically HIV-infected antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 2009, 199:693-701.
23. Stelzl E., Proll J., Bizon B., Niklas N., Danzer M., Hackl C., Stabentheiner S., Gabriel C., Kessler H.H. Human immunodeficiency virus type 1 drug resistance testing: evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit. J. Virol. Methods 2011, 178:94-97.
24. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Jensen M.A., Thielen A., Chapman D., Lewis M., James I., Heera J., Valdez H., Harrigan P.R. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 2011, 203:237-245.
25. Tsibris A.M., Korber B., Arnaout R., Russ C., Lo C.C., Leitner T., Gaschen B., Theiler J., Paredes R., Su Z., Hughes M.D., Gulick R.M., Greaves W., Coakley E., Flexner C., Nusbaum C., Kuritzkes D.R. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 2009, 4:e5683.
26. Varghese V., Shahriar R., Rhee S.Y., Liu T., Simen B.B., Egholm M., Hanczaruk B., Blake L.A., Gharizadeh B., Babrzadeh F., Bachmann M.H., Fessel W.J., Shafer R.W. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 2009, 52:309-315.
27. Wang C., Mitsuya Y., Gharizadeh B., Ronaghi M., Shafer R.W. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007, 17:1195-1201.